Skip to main content

Table 1 Baseline demographics and risk factors

From: Ezetimibe/Simvastatin 10/20 mg versus Rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency

 

Low Potency*

High Potency

 

E/S 10/20

(n = 189)

R 10

(n = 180)

Total

(N = 369)

E/S 10/20

(n = 125)

R 10

(n = 124)

Total

(N = 249)

   Male, n (%)

74 (39.2)

77 (42.8)

151 (40.9)

55 (44.0)

42 (33.9)

97 (39.0)

   Female, n (%)

115 (60.8)

103 (57.2)

218 (59.1)

70 (56.0)

82 (66.1)

152 (61.0)

   Mean Age, y (SD)

63.4 (9.3)

63.5 (10.6)

63.5 (10.0)

62.9 (10.5)

62.4 (9.1)

62.7 (9.8)

   Race n (%)

      

White

189 (100)

180 (100)

369 (100)

125 (100)

122 (98.4)

247 (99.2)

Other

    

2 (1.6)

2 (0.8)

   BMI <30 kg/m2‡ (%)

128 (67.7)

134 (74.4)

262 (71.0)

88 (70.4)

87 (70.2)

175 (70.3)

   BMI ≥30 kg/m2‡ (%)

61 (32.3)

46 (25.6)

107 (29.0)

36 (28.8)

37 (29.8)

73 (29.3)

Risk factors [n (%)]

      

   CHD

90 (47.6)

84 (46.7)

174 (47.2)

62 (49.6)

60 (48.4)

122 (49.0)

   Diabetes

60 (31.7)

52 (28.9)

112 (30.4)

35 (28.0)

26 (21.0)

61 (24.5)

   Ex-smoker

37 (19.6)

44 (24.4)

81 (22.0)

40 (32.0)

26 (21.0)

66 (26.5)

   Non smoker

94 (49.7)

87 (48.3)

181 (49.1)

50 (40.0)

51 (41.1)

101 (40.6)

   Smoker

58 (30.7)

49 (27.2)

107 (29.0)

35 (28.0)

47 (37.9)

82 (32.9)

  1. E = ezetimibe; BMI = body mass index; CHD = coronary heart disease; n = number; R = rosuvastatin; S = simvastatin; SD = standard deviation; y = year
  2. *Low potency stratum included: simvastatin 20 mg, pravastatin 40 mg, fluvastatin 80 mg, atorvastatin 10 mg
  3. High potency stratum included: simvastatin 40 mg, atorvastatin 20 mg, rosuvastatin 5 mg
  4. Missing data for 1 patient in the high potency EZ/Simva group